Study May Boost Use of Merck Lung-Cancer Drug

Share:
Facebook Twitter Google+

Patients with advanced lung cancer who took Merck’s immune-boosting drug Keytruda as their first treatment lived longer on average than those who received chemotherapy, a new study shows.
WSJ.com: What’s News US

Commenti

commenti